Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aminopterin in Persistent or Recurrent Endometrial Carcinoma
NCT00003821Phase 2Withdrawn
- Sponsor
- Sanofi
- Start
- Jan 1998
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aminopterin in endometrial carcinoma, sponsored by Sanofi. Primary endpoint: Antitumor Activity. Planned start Jan 1998; status: withdrawn.
02
Drugs
aminopterin
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT00003821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003821.